Kazia Therapeutics Limited
KZIAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Kazia Therapeutics Limited focuses on Biotechnology services and products. Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. Valued at $140.7M, KZIA is a micro-cap name in its sector. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Market Cap
$140.7M
Beta
2.15
P/E (TTM)
—
P/E (Fwd)
-1004.96
EPS (TTM)
$-7.60
EPS (Fwd)
$-0.01
ROE
-106.9%
ROA
-25.7%
Cash
$69.5M
Total Debt
$98,807
Free CF
$1.1M
52W Change
52.9%
Annual Financials
Cash vs Debt
Where KZIA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, KZIA finished 14.12% above its 150-day moving average ($11.05) and 20.44% above its 200-day moving average ($10.47). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KZIA overbought or oversold?
At the September 3, 2026 close, KZIA's RSI(14) was 47.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $69.5M in cash comfortably exceeding the $99K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $1.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -106.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, KZIA tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Kazia Therapeutics Limited and its sector.